{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:43:35Z","timestamp":1782146615842,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.semerg.2017.10.003","type":"journal-article","created":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T23:16:23Z","timestamp":1512170183000},"page":"23-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Seguridad de los iSGLT-2. Revisi\u00f3n de las reacciones adversas notificadas a nivel nacional"],"prefix":"10.1016","volume":"44","author":[{"given":"O.","family":"Esteban-Jim\u00e9nez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Navarro-Pem\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Urieta-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2017.10.003_bib0100","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s00125-011-2336-9","article-title":"Prevalence of diabetes mellitus and impaired glucose regulation in Spain: The Di@bet.es Study","volume":"55","author":"Soriguer","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.semerg.2017.10.003_bib0105","unstructured":"Ficha t\u00e9cnica de Forxiga [consultado Feb 2017]. Disponible en: http:\/\/www.aemps.gob.es\/cima\/fichasTecnicas.do?metodo=detalleForm"},{"key":"10.1016\/j.semerg.2017.10.003_bib0110","unstructured":"Ficha t\u00e9cnica de Invokana [consultado Feb 2017]. Disponible en: http:\/\/www.aemps.gob.es\/cima\/fichasTecnicas.do?metodo=detalleForm"},{"key":"10.1016\/j.semerg.2017.10.003_bib0115","unstructured":"Ficha t\u00e9cnica de Jardiance [consultado Feb 2017]. Disponible en: http:\/\/www.aemps.gob.es\/cima\/fichasTecnicas.do?metodo=detalleForm"},{"key":"10.1016\/j.semerg.2017.10.003_bib0120","unstructured":"Medicamentos sujetos a seguimiento adicional. Agencia Espa\u00f1ola del Medicamentos y Productos Sanitarios. Actualizado a fecha 26\/1\/16 [consultado Feb 2017]. Disponible en: https:\/\/www.aemps.gob.es\/vigilancia\/medicamentosUsoHumano\/seguimiento_adicional.htm"},{"key":"10.1016\/j.semerg.2017.10.003_bib0125","unstructured":"Alem\u00e1n JJ, Artola S, Franch J, Mata M, Millaruelo JM y Sangr\u00f3s J, en nombre de la RedGDPS. Recomendaciones para el tratamiento de la diabetes mellitus tipo2: control gluc\u00e9mico. 2014 [consultado 1 Feb 2017]. Disponible en http:\/\/www.redgdps.org\/"},{"issue":"Suppl 1","key":"10.1016\/j.semerg.2017.10.003_bib0130","first-page":"S1","article-title":"Standards of medical care in Diabetes-2016 (Position Statement)","volume":"39","year":"2016","journal-title":"Diabetes Care."},{"key":"10.1016\/j.semerg.2017.10.003_bib0135","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4158\/EP151126.CS","article-title":"Consensus statement by the American Association of Clinical Endocrinologist and American College of endocrinology on the comprehensive type2 diabetes management algorithm \u2014 2016 executive summary","volume":"22","author":"Garber","year":"2016","journal-title":"Endocr Pract."},{"key":"10.1016\/j.semerg.2017.10.003_bib0140","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semerg.2017.10.003_bib0145","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1210\/jc.2016-3446","article-title":"All-cause mortality in patients with diabetes under treatment with dapagliflozin: A population-based, open-cohort study in THIN database","volume":"102","author":"Toulis","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.semerg.2017.10.003_bib0150","doi-asserted-by":"crossref","DOI":"10.1185\/03007995.2016.1161608","article-title":"Practical considerations for the use of sodium-glucose co-transporter type2 inhibitors in treating hyperglycemia in type2 diabetes","volume":"32","author":"Lam","year":"2016","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.semerg.2017.10.003_bib0155","unstructured":"Recomendaciones sobre el riesgo de cetoacidosis diab\u00e9tica asociada al uso de canagliflozina, dapagliflozina y empagliflozina. Recomendaciones del Comit\u00e9 para la Evaluaci\u00f3n de Riesgos en Farmacovigilancia europeo (PRAC). Fecha de publicaci\u00f3n: 12 de febrero de 2016. Agencia Espa\u00f1ola del Medicamentos y Productos Sanitarios [consultado Feb 2017]. Disponible en: https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2016\/docs\/NI-MUH_FV_02-glifozinas.pdf"},{"key":"10.1016\/j.semerg.2017.10.003_bib0160","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr Pract."},{"key":"10.1016\/j.semerg.2017.10.003_bib0165","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: A systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.semerg.2017.10.003_bib0170","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.semerg.2017.10.003_bib0175","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.semerg.2017.10.003_bib0180","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR), 2016 [consultado Feb 2017]. Disponible en: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm505860.htm"},{"key":"10.1016\/j.semerg.2017.10.003_bib0185","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.2337\/dc16-2200","article-title":"Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: Caution regarding concomitant use of NSAIDs and iodinated contrast media","volume":"40","author":"Heyman","year":"2017","journal-title":"Diabetes Care."},{"key":"10.1016\/j.semerg.2017.10.003_bib0190","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359317303027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359317303027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T10:38:05Z","timestamp":1535193485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359317303027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1138359317303027"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2017.10.003","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seguridad de los iSGLT-2. Revisi\u00f3n de las reacciones adversas notificadas a nivel nacional","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2017.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}